OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumors that have been shown to overexpress clusterin, including but not limited to, any of the following: * Prostate cancer * Renal cell carcinoma * Non-small cell lung cancer * Bladder cancer * Breast cancer * Ovarian cancer * Metastatic or locally recurrent disease * Refractory to standard curative therapy or no standard curative therapy exists * Patients with prostate cancer must be hormone refractory (i.e., have documented evidence of progression while receiving androgen ablative therapy) * Measurable or nonmeasurable disease * Measurable disease defined as measurable lesion ≥ 20 mm by x-ray, physical exam, or nonspiral CT scan or ≥ 10 mm by spiral CT scan * No documented CNS metastases * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * Absolute granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin normal * Creatinine ≤ 2 times upper limit of normal (ULN) * AST and ALT ≤ 1.5 times ULN * PT/INR and PTT normal * No uncontrolled pain * No known bleeding disorder * No history of serious allergic reaction to taxane (paclitaxel or docetaxel) * No preexisting peripheral neuropathy ≥ grade 2 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other serious illness or medical conditions that would preclu…